Use Options For a Chance To Buy GEVA at a 22% Discount

Looking back to 97 days ago, Synageva BioPharma Corp (GEVA) priced a 2,750,000 share secondary stock offering at $56.63 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Monday, the stock is now 14.5% higher than the offering price.

Investors who did not participate in the offering but would be a buyer of GEVA at a cheaper price, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July 2014 put at the $55 strike, which has a bid at the time of this writing of $2.95. That would result in a cost basis of $52.05 per share before broker commissions in the scenario where the contract is exercised. If the contract is never exercised, the put seller would still keep the premium, which represents a 5.4% return against the $55.00 purchase commitment, or a 9.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

START SLIDESHOW:
Top YieldBoost Puts of of Stocks with Recent Secondaries »

Secondaries can often present buying opportunities for bullish investors interested in purchasing shares, because the sudden extra supply of stock tends to require that the offering be priced at an attractive discount to where the stock had previously been trading before the offering announcement. That can also introduce near-term volatility which improves the premiums a put seller can achieve. Selling a put does not give an investor access to GEVA's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. The chart below shows the one year performance of GEVA shares, versus its 200 day moving average:

Synageva BioPharma Corp Chart

Looking at the chart above, GEVA's low point in its 52 week range is $38.58 per share, with $70.50 as the 52 week high point — that compares with a last trade of $66.36.

According to the ETF Finder at ETF Channel, GEVA makes up 1.49% of the SPDR S&P Biotech ETF ( XBI) which is trading up by about 0.2% on the day Monday.

More from Stocks

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Chipotle's New CEO Has Set its Path for Redemption

Chipotle's New CEO Has Set its Path for Redemption

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced